Long-term clinical outcomes of genicular nerve radiofrequency ablation for chronic knee pain using a three-tined electrode for expanded nerve capture

Koshi, Edvin; Meiling, James B.; Conger, Aaron; McCormick, Zachary L.; Burnham, Taylor

doi:10.1016/j.inpm.2021.100003

Cited by 7 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The degree of improvement in our patients is similar to other studies with active comparator groups (13)(14)(15)(16), with a similar pattern of diminution of effect at 12 weeks. The beneficial effect shown with GNB was similar to the reported effect of radiofrequency ablation, although the duration of the effect of ablation may be longer (34). We observed a diminution of the effect in the active group in the latter part of the trial, with not all improvements remaining statistically significant to week 12.…”

Section: Discussionmentioning

confidence: 99%

Genicular Nerve Block for Pain Management in Patients With Knee Osteoarthritis: A Randomized Placebo‐Controlled Trial

Shanahan

Robinson

Lyne

et al. 2022

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective This study was undertaken to determine the efficacy of ultrasound‐guided genicular nerve block (GNB) for the management of knee pain in patients with knee osteoarthritis. Methods We performed a 12‐week parallel‐group, placebo‐controlled randomized trial of GNB. Within 2 weeks of randomization, patients with knee osteoarthritis in the active arm received 3 injections of 5.7 mg celestone chronodose (1 ml) and 0.5% bupivacaine (3 ml) to the inferomedial, superomedial, and superolateral genicular nerves; patients with knee osteoarthritis in the placebo arm received injections of normal saline. At baseline and at weeks 2, 4, 8, and 12, patients recorded their pain and disability on a 100‐mm visual analog scale (VAS) (the primary outcome measure), the Western Ontario and McMasters Universities Osteoarthritis Index (WOMAC), and the Intermittent and Constant Osteoarthritis Pain scale. Statistical significance was set at a 2‐sided Type I error of α = 0.0125 for comparisons at each of the 4 time points. We used a global perceived effect scale to measure patient satisfaction. Results The 59 patients (36 female, 23 male) who completed the trial had a mean ± SD age of 68.2 ± 8.6 years. Patients in the active group reported improvements in pain scores at 2, 4, 8, and 12 weeks with a diminution of the effect over time. VAS scores at baseline and at weeks 2, 4, 8, and 12 in the active group (n = 31) versus placebo group (n = 28) were 6.2 versus 5.3 (P = 0.294), 2.7 versus 4.7 (P < 0.001), 3.2 versus 5.1 (P < 0.001), 3.9 versus 4.9 (P < 0.001), and 4.6 versus 5.1 (P = 0.055), respectively. Total WOMAC scores at baseline and at weeks 2, 4, 6, 8, and 12 in the active group versus the placebo group were 54.5 versus 48.1 (P = 0.177), 32.9 versus 44.4 (P < 0.001), 33.7 versus 45.8 (P < 0.001), 39.2 versus 44.8 (P = 0.001), and 42.65 versus 45.1 (P = 0.012), respectively. Conclusion GNB offers short‐term pain relief for knee osteoarthritis.

show abstract

Section: Discussionmentioning

confidence: 99%